HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lisa D Pedicone Selected Research

peginterferon alfa-2b (Pegintron)

5/2014Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
3/2013Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
1/2013Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
9/2011Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
8/2010Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
8/2009Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lisa D Pedicone Research Topics

Disease

16Infections
02/2017 - 08/2009
16Chronic Hepatitis C
05/2014 - 08/2009
7Hepatitis C
06/2019 - 08/2009
6Anemia
11/2013 - 11/2010
3Fibrosis (Cirrhosis)
03/2013 - 09/2012
2Dysgeusia (Parageusia)
05/2014 - 08/2010
2Body Weight (Weight, Body)
09/2012 - 08/2009
1Lymphopenia (Lymphocytopenia)
04/2014
1Acquired Immunodeficiency Syndrome (AIDS)
03/2013
1Neutropenia
01/2013
1Reinfection
09/2012
1Viremia
09/2012
1Drug-Related Side Effects and Adverse Reactions
08/2012
1Hemolytic Anemia
02/2012
1Cytopenia
02/2012
1Hemolysis
11/2010
1Virus Diseases (Viral Diseases)
08/2010

Drug/Important Bio-Agent (IBA)

19Ribavirin (Virazole)FDA LinkGeneric
05/2014 - 08/2009
11N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
05/2014 - 08/2010
6peginterferon alfa-2b (Pegintron)FDA Link
05/2014 - 08/2009
3Antiviral Agents (Antivirals)IBA
06/2019 - 08/2010
3Protease Inhibitors (Protease Inhibitor)IBA
05/2014 - 08/2010
3Hemoglobins (Hemoglobin)IBA
03/2013 - 09/2012
2peginterferon alfa-2a (Pegasys)FDA Link
04/2014 - 08/2009
2ErythropoietinFDA Link
11/2013 - 03/2013
2InterferonsIBA
11/2013 - 02/2012
2Interferon-alpha (Interferon Alfa)IBA
02/2012 - 07/2010
1Hepatitis C AntibodiesIBA
02/2017
1CreatinineIBA
03/2013
1Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA
03/2013
1Amino AcidsFDA Link
01/2013
1ORALIT (ORS)IBA
09/2012
1Inosine TriphosphataseIBA
02/2012
1RNA (Ribonucleic Acid)IBA
09/2011
1HematinicsIBA
11/2010
1InterleukinsIBA
07/2010

Therapy/Procedure

11Therapeutics
05/2014 - 07/2010
4Drug Tapering
04/2014 - 11/2010
1Transplantation
09/2012
1Liver Transplantation
09/2012
1Duration of Therapy
10/2010